Study examines malaria preventive therapy during pregnancy and outcomes for infants in Africa

February 12, 2013

Among pregnant women in sub-Saharan Africa, intermittent preventive therapy for malaria with 3 or more doses of the drug regimen sulfadoxine-pyrimethamine was associated with a higher birth weight and lower risk of low birth weight than the current standard 2-dose regimen, according to a review and meta-analysis of previous studies published in the February 13 issue of JAMA.

"Intermittent with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen. However, 2 doses may not provide protection during the last 4 to 10 weeks of pregnancy, a for fetal weight gain," according to background information in the article. "Furthermore, increasing sulfadoxine-pyrimethamine resistance, which results in a progressive decrease of the duration of the prophylactic effect, may also require more frequent dosing."

Kassoum Kayentao, M.D., of the Liverpool School of Tropical Medicine, Liverpool, United Kingdom, and colleagues conducted a review and meta-analysis to evaluate whether 3 or more doses of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine are associated with higher or a lower risk of (LBW; less than 5.5 lbs.) than a 2-dose regimen. After a review of the medical literature, the researchers identified 7 trials that met inclusion criteria. These trials included 6,281 pregnancies.

Analysis of the data indicated that women in the ≥ 3-dose group had a 20 percent lower risk of having a LBW infant. The absolute risk reduction was 33 per 1,000 women, from a median (midpoint) risk of 167 per 1,000 in the 2-dose group to 134 per 1,000 in the ≥ 3-dose recipients (number needed to treat = 31). The median birth weight in the 2-dose group was 6.3 lbs., and on average 2 ounces higher in the ≥ 3-dose group.

"The association was consistent across a wide range of sulfadoxine-pyrimethamine resistance. There was no evidence of small-study bias. The ≥ 3-dose group had less placental malaria," the authors write. "There were no differences in rates of serious adverse events."

"These data provide support for the new World Health Organization (WHO) recommendation that intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine be provided at each scheduled focused antenatal-care [before birth] visit in the second and third trimesters in all settings in which intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine is recommended. Future research should focus on how best to implement the updated WHO guidelines for intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and specifically their integration with focused antenatal care. Continued monitoring of the association between population-level sulfadoxine-pyrimethamine resistance and the effectiveness of intermittent preventive therapy during is required," the researchers conclude.

Explore further: Fewer iron supplements during pregnancy work just as well for preventing anemia

More information: JAMA 2013;309(6):594-604

Related Stories

Fewer iron supplements during pregnancy work just as well for preventing anemia

July 10, 2012
Taking iron supplements one to three times a week instead of every day is just as effective at preventing anaemia in pregnant women, according to the findings of a new Cochrane systematic review. The authors of the review ...

Intensive-dose statin therapy associated with increased risk of diabetes

June 21, 2011
An analysis of data from previously published studies indicates that intensive-dose statin therapy is associated with an increased risk of new-onset diabetes compared with moderate-dose therapy, according to a study in the ...

Combination drug treatment can cut malaria by 30 percent

April 2, 2012
Malaria infections among infants can be cut by up to 30 per cent when antimalarial drugs are given intermittently over a 12 month period, a three-year clinical trial in Papua New Guinea has shown.

Recommended for you

Women exposed to smoke while in womb more likely to miscarry

July 13, 2017
Women exposed to cigarette smoke while in their mothers' wombs are more likely to experience miscarriage as adults, according to new research from the University of Aberdeen.

Lack of a hormone in pregnant mice linked to preeclampsia

June 30, 2017
(Medical Xpress)—A team of researchers from Singapore, the Netherlands and Turkey has isolated a hormone in pregnant mice that appears to be associated with preeclampsia—a pregnancy-related condition characterized by ...

Aspirin reduces risk of pre-eclampsia in pregnant women

June 28, 2017
Taking a low-dose aspirin before bed can reduce the risk of pre-eclampsia, which can cause premature birth and, in extreme cases, maternal and foetal death.

The biology of uterine fluid: How it informs the fetus of mom's world

June 22, 2017
A developing fetus bathes in a mixture of cellular secretions and proteins unique to its mother's uterus. Before fertilization, the pH of uterine fluid helps create a conducive environment for sperm migration, and afterward, ...

New clues in puzzle over pre-eclampsia and cholesterol regulation

June 21, 2017
Scientists studying a mystery link between the dangerous pregnancy complication pre-eclampsia and an increased risk of heart disease in later life for both mother and child have uncovered important new clues.

Are maternal hormones different when carrying a boy or a girl?

June 15, 2017
With advances in prenatal testing it's now possible to find out whether a pregnancy will result in a male or female baby as early as eight weeks' gestation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.